Dr. Neil Shah CML Chronic Myeloid Leukemia
Dr. Neil Shah is an Assistant Professor, Division of Hematology/Oncology, University of California, San Francisco (UCSF) School of Medicine
Extract of http://cancer.ucsf.edu/people/shah_neil.php
VIDEOS
Comorbidities Can Affect CML Treatment Decisions
July 25, 2019, OncLiveTV
Dr. Shah on TKI Treatment Discontinuation in CML
April 24, 2019, OncLiveTV
Dr. Shah on Investigational Agents in CML
January 29, 2019, OncLiveTV
Dr. Shah on Frontline Considerations for the Treatment of CML
October 5, 2018, OncLiveTV
What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology
What are the efficacy and safety considerations of nilotinib therapy?
April 29, 2016, MediCom Oncology
What are the efficacy and safety considerations of bosutinib therapy?
April 29, 2016, MediCom Oncology
CML Horizons 2014: Outlook - the future of CML therapy (Neil Shah)
May 20, 2014, cmladvocates
The DASISION chronic myeloid leukaemia trial – ASH2010
February 18, 2011, ecancer.tv
Comorbidities Can Affect CML Treatment Decisions
July 25, 2019, OncLiveTV
Dr. Shah on TKI Treatment Discontinuation in CML
April 24, 2019, OncLiveTV
Dr. Shah on Investigational Agents in CML
January 29, 2019, OncLiveTV
Dr. Shah on Frontline Considerations for the Treatment of CML
October 5, 2018, OncLiveTV
What are the efficacy and safety considerations of dasatinib therapy?
April 29, 2016, MediCom Oncology
What are the efficacy and safety considerations of nilotinib therapy?
April 29, 2016, MediCom Oncology
What are the efficacy and safety considerations of bosutinib therapy?
April 29, 2016, MediCom Oncology
CML Horizons 2014: Outlook - the future of CML therapy (Neil Shah)
May 20, 2014, cmladvocates
The DASISION chronic myeloid leukaemia trial – ASH2010
February 18, 2011, ecancer.tv
ARTICLES
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
October 24, 2020, Taylor & Francis Online
Expert Highlights Frontline Advancements in Treatment Landscape for CML
September 19, 2019, Targeted Oncology
Comorbidities Can Affect CML Treatment Decisions
July 25, 2019, Oncology Nursing News
TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23, 2019, OncLive
Emerging Agents, TKI Discontinuation Focal Points of CML Research
October 29, 2018, OncLive
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
October 24, 2020, Taylor & Francis Online
Expert Highlights Frontline Advancements in Treatment Landscape for CML
September 19, 2019, Targeted Oncology
Comorbidities Can Affect CML Treatment Decisions
July 25, 2019, Oncology Nursing News
TKI Discontinuation Criteria Established in Updated NCCN CML Guideline
March 23, 2019, OncLive
Emerging Agents, TKI Discontinuation Focal Points of CML Research
October 29, 2018, OncLive
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).